The Center for Medicare and Medicaid Services (CMS) has generously agreed to cover the costs of ECP and the related monitoring for patients enrolled in the ECP Trial.
Mallinckrodt Pharmaceuticals, Therakos has provided an unrestricted research grant to Washington University for the conduct of this study.